Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Unravelling the synergistic potential of Olibanum extract and Bacillus clausii in combating intestinal cryptosporidiosis in immunosuppressed mice. Local targets link to admitted publications; unresolved targets remain external evidence.
Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals
10.1016/s0140-6736(16)31593-8 · 2016 · External reference
Public health risks associated with food-borne parasites
2018 · External reference
Morbidity, mortality, and long-term consequences associated with diarrhoea from Cryptosporidium infection in children younger than 5 years: a meta-analyses study
10.1016/s2214-109x(18)30283-3 · 2018 · External reference
A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium
10.1016/s1473-3099(14)70772-8 · 2015 · External reference
Frequency of Giardia spp. and Cryptosporidium spp. in domestic and captive wild animals in the north of Veracruz, Mexico
2023 · External reference
A hundred-year retrospective on cryptosporidiosis
10.1016/j.pt.2008.01.002 · 2008 · External reference
Taxonomy and molecular epidemiology of Cryptosporidium and Giardia - a 50 year perspective (1971-2021
2021 · External reference
Cryptosporidium species and subtypes identified in human domestic cases through the national microbiological surveillance programme in Sweden from 2018 to 2022
10.1186/s12879-024-09049-x · 2024 · External reference
Cryptosporidium species in humans and animals: current understanding and research needs
10.1017/s0031182014001085 · 2014 · External reference
Evidence for a structural role for acid-fast lipids in oocyst walls of Cryptosporidium, Toxoplasma, and Eimeria
10.1128/mbio.00387-13 · 2013 · External reference
Pathogenic mechanisms of Cryptosporidium and Giardia
10.1016/j.pt.2017.02.006 · 2017 · External reference
Use of nitazoxanide for gastrointestinal tract infections: treatment of protozoan parasitic infection and beyond
10.1007/s11908-006-0003-y · 2006 · External reference
Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni
10.1128/aac.01159-06 · 2007 · External reference
Update on nitazoxanide: a multifunctional chemotherapeutic agent
10.2174/1570163814666170727130003 · 2018 · External reference
High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial
10.1186/1471-2334-9-195 · 2009 · External reference
Molecular pathogenesis of Cryptosporidium and advancements in therapeutic interventions
10.1051/parasite/2025001 · 2025 · External reference
The first commercially approved efficacious cryptosporidium vaccine protecting New-Born calves from severe diarrhea
10.1016/j.vetvac.2024.100054 · 2024 · External reference
Anti-Toxoplasma activities of some Egyptian plant extracts: an in vitro study
10.1007/s11686-022-00633-2 · 2022 · External reference
Herbal-based compounds: a review on treatments of cryptosporidiosis
10.1016/j.ijpddr.2024.100521 · 2024 · External reference
Anti-cryptosporidial drug-discovery challenges and existing therapeutic avenues: a “One-Health” concern
10.3390/life14010080 · 2024 · External reference
Treating cryptosporidiosis: a review on drug discovery strategies
10.1016/j.ijpddr.2024.100542 · 2024 · External reference
Frankincense: therapeutic properties
10.5604/17322693.1200553 · 2016 · External reference
Characterization of archaeological frankincense by gas chromatography-mass spectrometry
10.1016/j.chroma.2003.10.016 · 2004 · External reference
Frankincense and myrrh essential oils and burn incense fume against micro-inhabitants of sacral ambients. Wisdom of the ancients?
10.1016/j.jep.2018.03.003 · 2018 · External reference
Efficacy of olibanum and propolis medicinal extracts versus metronidazole in Giardia lamblia experimentally infected mice
2020 · External reference
Evaluation of the therapeutic effect of Olibanum extract against enteric and intramuscular phases of trichinosis in experimentally infected mice
10.1017/s0022149x23000214 · 2023 · External reference
Terpenoids from the Oleo-Gum-Resin of Boswellia serrata and their antiplasmodial effects in vitro
10.1055/s-0043-116943 · 2017 · External reference
Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic
10.1038/nrgastro.2014.66 · 2014 · External reference
Mechanisms of action of probiotics
10.1093/advances/nmy063 · 2019 · External reference
Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial
10.1111/j.1365-2036.2004.02274.x · 2004 · External reference
Probiotics L. acidophilus and B. clausii modulate gut microbiota in Th1- and Th2-biased mice to Ameliorate Salmonella Typhimurium-induced diarrhea
10.1007/s12602-018-9436-5 · 2019 · External reference
In vitro and in vivo evaluation of Bacillus clausii against Schistosoma mansoni
10.1016/j.actatropica.2022.106669 · 2022 · External reference
A study on the effect of Myrtus communis and Olibanum on Giardia lamblia infection in Egypt
2011 · External reference
Beta-boswellic acid and ethanolic extract of olibanum regulating the expression levels of CREB-1 and CREB-2 genes
2019 · External reference
Antiparasitic and immunomodulating effects of nitazoxanide, ivermectin and selenium on Cryptosporidium infection in diabetic mice
2021 · External reference
The controverted therapeutic efficacy of Allium sativum and Artemisia herba-alba extracts on Cryptosporidium-infected mice
10.3855/jidc.17360 · 2023 · External reference
Potential efficacy of curcumin and curcumin nanoemulsion against experimental cyclosporiasis
10.21608/puj.2023.237883.1223 · 2023 · External reference
Immunosuppression with cyclophosphamide favors reinfection with recombinant Toxoplasma gondii strains
10.1051/parasite/2012193249 · 2012 · External reference
Evaluation of the therapeutic efficacy of some essential oils in experimentally immunosuppressed mice infected with Cryptosporidium parvum
10.1007/s12639-023-01621-7 · 2023 · External reference
Therapeutic and antioxidant potential of bionanofactory Ochrobactrum sp.-mediated magnetite and zerovalent iron nanoparticles against acute experimental toxoplasmosis
10.1371/journal.pntd.0011655 · 2023 · External reference
Isatin-1,2,3-triazole derivatives: synthesis, molecular docking and evaluation against acute experimental toxoplasmosis
10.1016/j.actatropica.2024.107471 · 2024 · External reference
Potent efficiency of the novel nitazoxanide-loaded nanostructured lipid carriers against experimental cyclosporiasis
2023 · External reference
Anti-protozoal potential of electrospun polymeric nanofiber composite membranes for treatment of contaminated drinking water
10.1080/20477724.2025.2460006 · 2025 · External reference
Past, current, and potential treatments for cryptosporidiosis in humans and farm animals: a comprehensive review
10.3389/fcimb.2023.1115522 · 2023 · External reference
Medicinal plants as a source of antiparasitics: an overview of experimental studies
10.1080/20477724.2023.2179454 · 2023 · External reference
Rosmarinus Officinalis L. essential oil: in Silico molecular docking and in vivo nematocidal activity on intestinal and muscular trichinellosis
10.1186/s12906-025-04996-7 · 2025 · External reference
Interaction between intestinal parasites and the gut microbiota: implications for the intestinal immune response and host defence
10.3390/pathogens13080608 · 2024 · External reference
Anti-inflammatory and anti-cancer activities of frankincense: targets, treatments and toxicities
10.1016/j.semcancer.2020.01.015 · 2022 · External reference
Effect of Boswellia serrata on intestinal motility in rodents: inhibition of diarrhoea without constipation
10.1038/sj.bjp.0706740 · 2006 · External reference
Inter-tree variation in the chemical composition of Boswellia papyrifera oleo-gum-resin
2022 · External reference
Comparative phytochemical analyses of resins of Boswellia species (B. papyrifera (Del.) Hochst., B. neglecta S. Moore, and B. rivae Engl.) from northwestern, southern, and southeastern Ethiopia
2014 · External reference
Distribution of the anti-inflammatory and anti-depressant compounds: incensole and incensole acetate in genus Boswellia
10.1016/j.phytochem.2019.01.007 · 2019 · External reference
Comparative secretome analysis of four isogenic Bacillus clausii probiotic strains
10.1186/1477-5956-11-28 · 2013 · External reference
Bacillus clausii probiotic strains: antimicrobial and immunomodulatory activities
10.1097/01.mcg.0000128925.06662.69 · 2004 · External reference
Bacillus clausii effect on gene expression pattern in small bowel mucosa using DNA microarray analysis
2005 · External reference
Protective action of Bacillus clausii probiotic strains in an in vitro model of Rotavirus infection
10.1038/s41598-020-69533-7 · 2020 · External reference
Cryptosporidium pathogenicity and virulence
10.1128/cmr.00076-12 · 2013 · External reference
Cytokines evaluation in nasal lavage of allergic children after Bacillus clausii administration: a pilot study
10.1046/j.1399-3038.2003.00102.x · 2004 · External reference
Review of the chemical composition, pharmacological effects, pharmacokinetics, and quality control of Boswellia carterii
2022 · External reference
The FDA-approved oral drug nitazoxanide amplifies host antiviral responses and inhibits ebola virus
10.1016/j.isci.2019.07.003 · 2019 · External reference
Innate immune responses against Cryptosporidium parvum infection
10.1111/pim.12020 · 2013 · External reference
A novel piperazine-based drug lead for cryptosporidiosis from the medicines for malaria venture open-access malaria box
10.1128/aac.01505-17 · 2018 · External reference
